May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Optic Nerve Damage Score – a Simple, Efficient, and Reliable Endpoint for Experimental Optic Neuropathy
Author Affiliations & Notes
  • G. Barnes
    Alcon Research Ltd, Fort Worth, TX
  • B. Li
    Alcon Research Ltd, Fort Worth, TX
  • I.–H. Pang
    Alcon Research Ltd, Fort Worth, TX
  • D. Cantu–Crouch
    Alcon Research Ltd, Fort Worth, TX
  • A. Clark
    Alcon Research Ltd, Fort Worth, TX
  • W.F. Holt
    Alcon Research Ltd, Fort Worth, TX
  • Footnotes
    Commercial Relationships  G. Barnes, Alcon Research Ltd E; B. Li, Alcon Research Ltd E; I. Pang, Alcon Research Ltd E; D. Cantu–Crouch, Alcon Research Ltd E; A. Clark, Alcon Research Ltd E; W.F. Holt, Alcon Research Ltd E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1315. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Barnes, B. Li, I.–H. Pang, D. Cantu–Crouch, A. Clark, W.F. Holt; Optic Nerve Damage Score – a Simple, Efficient, and Reliable Endpoint for Experimental Optic Neuropathy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1315.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To determine whether the optic nerve damage score (ONDS), a simple histological endpoint measure, can be used to estimate retinal ganglion cell (RGC) loss caused by the transient global ocular ischemia/reperfusion (I/R) model.Methods: In Brown Norway rats, right eyes were subjected to transient periods of ischemia of 45, 60, or 75 min, by increasing the intraocular pressure (IOP) above systolic blood pressure (i.e. > 130 mm Hg). Two endpoints, morphologic scoring of optic nerve damage (by masked readers) from p–phenylenediamine–stained optic nerve cross sections and quantification of the dextran tetramethylrhodamine (DTMR) labeled RGCs in whole mounted retinas, were used to assess the degree of I/R induced damage. Results: Two weeks after 45, 60, or 75 min of retinal ischemia followed by reperfusion, the ONDS (ranges from 1 for a normal optic nerve to 5 for global nerve damage) was 1.7 ± 0.1 (N=7), 3.1 ± 0.2 (N=12), or 3.9 ± 0.1 (N=7), respectively. Meanwhile, loss of DTMR–labeled RGCs was 23 ± 10% (N=7), 47 ± 5% (N=11), or 72 ± 5% (N=6), respectively. Both ONDS and RGC counts correlated highly significantly (P < 0.001) with ischemia duration. Pretreatment with MK801 (1 mg/kg, ip, 1 h prior to a 60–min ischemia) significantly reduced the ONDS (1.6 ± 0.1, N=10) and RGC loss (26%, N=4) when compared to the vehicle–treated animals. Conclusions: The ONDS is a simple and reliable endpoint measure that can be used to evaluate neuroprotective drug efficacy and provides similar efficacy data when compared to RGC loss from counting fluorescent labeled RGCs. The ONDS is a particularly useful endpoint measure for drug screening of compounds for retinal protection.

Keywords: neuroprotection • ischemia • ganglion cells 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.